2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10679
    PF-03049423 free base 954138-07-9 98%
    PF-03049423 (Compound PF-5) free base is a potent and highly selective phosphodiesterase-5A inhibitor with an IC50 of about 0.2 nM for rat and human platelet enzyme. PF-03049423 free base can be used for the research of acute ischaemic stroke.
    PF-03049423 free base
  • HY-10711
    ALX-5407 571147-18-7 98%
    ALX-5407 ((R)-NFPS) is a selective and orally active glycine transporter GlyT1 inhibitor with an IC50 value of 3 nM. ALX-5407 can be used the research of N-methyl-D-aspartate-receptor function and schizophrenia.
    ALX-5407
  • HY-10712
    Org-24598 372198-97-5 98%
    Org-24598 is an inhibitor of glycine transporter 1 GlyT-1 . Org-24598 can inhibit the specific binding of [3H] CHIBIA-3007 to the rat brain membranes with a Ki value of 16.9 nM.
    Org-24598
  • HY-10713
    Org-24598 lithium 722456-08-8 98%
    Org-24598 lithium is an inhibitor of glycine transporter 1 GlyT-1 . Org-24598 lithium can inhibit the specific binding of [3H] CHIBIA-3007 to the rat brain membranes with a Ki value of 16.9 nM.
    Org-24598 lithium
  • HY-10716
    PF-03463275 hydrochloride 1173177-11-1 98%
    PF-03463275 hydrochloride is a centrally penetrant, orally available, selective, and competitive GlyT1 (glycine transporter-1) reversible inhibitor, with a Ki of 11.6 nM. PF-03463275 hydrochloride has the potential for Schizophrenia research.
    PF-03463275 hydrochloride
  • HY-10792
    Eplivanserin 130579-75-8 98%
    Eplivanserin (SR-46349) is a potent, selective and orally active 5-HT2A receptor antagonist, with an IC50 of 5.8 nM in rat cortical membrane, and a Kd of 1.14 nM. Eplivanserin displays >20-fold selectivity more selective for 5-HT2A than 5-HT2B and 5-HT2C.
    Eplivanserin
  • HY-10800
    GSK-588045 876922-98-4 98%
    GSK-588045 is a potent 5-HT(1A/B/D) receptor antagonist. GSK-588045 shows high degree of selectivity over human ether-a-go-go related gene (hERG) potassium channels. GSK-588045 can be used for the research of neurological disease, such as depression and anxiety.
    GSK-588045
  • HY-10826
    DG051 free acid 929916-05-2 98%
    DG051 (free acid) is an effective inhibitor of leukotriene A4 hydrolase (LTA4H), with a Kd of 26 nM. It has high water solubility (greater than 30 mg/mL) and high oral bioavailability (over 80% across different species). DG051 (free acid) can be used in research related to myocardial infarction and stroke.
    DG051 free acid
  • HY-10827
    Kelatorphan 92175-57-0 99.57%
    Kelatorphan is a full inhibitor of enkephalin degrading enzymes.
    Kelatorphan
  • HY-10886
    MCOPPB 1028969-49-4 98%
    MCOPPB is an orally active and selective agonist of Nociceptin/Orphanin FQ–Receptor. MCOPPB inhibits signaling through the NOP receptor in the mouse brain. MCOPPB is used in anxiety disorders research.
    MCOPPB
  • HY-10955
    TTA-P1 918333-06-9 98%
    TTA-P1 is a potent state-independent compound inhibiting human T-type calcium channel. T-type calcium channels play a role in diverse physiological responses including neuronal burst firing, hormone secretion, and cell growth. TTA-P1 has the potential for the research of absence epilepsy.
    TTA-P1
  • HY-10975
    MK-0752 sodium 656810-87-6 98%
    MK-0752 sodium is a potent, orally active and specific γ-secretase inhibitor, showing dose-dependent reduction of Aβ40 with an IC50 of 5 nM in human SH-SY5Y cells. MK-0752 sodium crosses the blood-brain barrier. MK-0752 sodium reduces newly generated CNS Aβ in vivo.
    MK-0752 sodium
  • HY-10996
    KHS101 1262770-73-9 98%
    KHS101 is a small molecule that accelerates neuronal differentiation. KHS101 can distributes to the brain and resulted in a significant increase in neuronal differentiation.
    KHS101
  • HY-11045
    PF-03654746 935840-31-6 98%
    PF-03654746 is a potent and selective histamine H3 receptor antagonist with high brain penetration. PF-03654746 reduces allergen-induced nasal symptoms, might be a novel therapeutic strategy to further explore allergic rhinitis. PF-03654746 improves cognitive efficacy and disease-modifying effects in Alzheimer's disease (AD).
    PF-03654746
  • HY-11055
    KP 544 393856-87-6 98%
    KP 544 is a potent neurotrophic protein enhancer that amplifies nerve growth factor (NGF)-induced neurite outgrowth of PC12 cells and SH-SY5Y neuroblastoma cells. KP544 also enhances choline acetyltransferase activity. KP 544 selectively interact in the differentiation pathway downstream of MAPK in a manner that amplifies nerve growth factor and cyclic AMP effects and is also neuroprotective.
    KP 544
  • HY-11056
    PF-04363467 1010382-72-5 98%
    PF-04363467 is a highly preferring D3R antagonist. PF-04363467 produces dose-dependent changes in the EEG profile of freely moving rats. PF-4363467 attenuates opioid drug-seeking behavior without concomitant D2 side effects. PF-04363467 can be used for the study of addiction, cognitive and mental illness.
    PF-04363467
  • HY-11058
    BHF177 917896-43-6 98%
    BHF177 is a positive modulator of GABAB receptors that can block the interaction between nicotine and the brain's dopamine system, thereby reducing the addictive properties of nicotine. BHF177 is expected to be used in research related to smoking cessation.
    BHF177
  • HY-11084
    SNAP-7941 387825-78-7 98%
    SNAP-7941 is a selective antagonist with anxiolytic, antidepressant and appetite suppressant activities. SNAP-7941 showed promising biological activity in initial animal studies. SNAP-7941 targets the melanin concentrating hormone receptor MCH1 and has significant inhibitory potential. SNAP-7941 was shown to inhibit the centrally induced MCH-induced drinking effect in in vivo studies.
    SNAP-7941
  • HY-12125
    BMS-561388 benzenesulfonate 383368-51-2 98%
    BMS-561388 (benzenesulfonate) is a corticotropin-releasing factor receptor (CRFR) antagonist. BMS-561388 (benzenesulfonate) can be used for the research of neurological disease, such as anxiety and depression.
    BMS-561388 benzenesulfonate
  • HY-12130
    CP 154526 157286-86-7 98%
    CP 154526 is a potent, brain-penetrant and selective corticotropin-releasing factor receptor 1 (CRF1) antagonist with a Ki of 2.7 nM. CP 154526 shows selective for CRF1 over CRF2 (Ki = >10 μM). CP 154526 has anxiolytic activities.
    CP 154526
Cat. No. Product Name / Synonyms Application Reactivity